You are here

Clinical Trials: Cord Blood

Comment

Discuss
Body: Conditions:   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Myelofibrosis;   MDS;   Refractory Anemia;   Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Non-Hodgkin's Lymphoma;   Leukemia;   Lymphoma;   Multiple Myeloma;   Myelodysplastic Syndromes
Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
Sponsor:   Masonic Cancer Center, University of Minnesota
Recruiting
Body: Conditions:   Congenital Amegakaryocytic Thrombocytopenia;   Diamond-blackfan Anemia;   Leukemia;   Myelodysplastic Syndromes;   Severe Congenital Neutropenia
Interventions:   Biological: alemtuzumab;   Drug: busulfan;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: methotrexate;   Drug: methylprednisolone;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: umbilical cord blood transplantation
Sponsors:   University of California, San Francisco;   National Cancer Institute (NCI)
Completed
Body: Conditions:   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions:   Biological: anti-thymocyte globulin;   Biological: sargramostim;   Drug: busulfan;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: umbilical cord blood transplantation
Sponsors:   University of California, San Francisco;   National Cancer Institute (NCI)
Completed - verified September 2017
Body: Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Unusual Cancers of Childhood
Interventions:   Biological: anti-thymocyte globulin;   Biological: filgrastim;   Drug: busulfan;   Drug: carmustine;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: cytarabine;   Drug: etoposide;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: peripheral blood stem cell transplantation;   Procedure: umbilical cord blood transplantation;   Radiation: radiation therapy
Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
Terminated
Body: Condition:   Fanconi Anemia
Interventions:   Biological: anti-thymocyte globulin;   Biological: filgrastim;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: methylprednisolone;   Biological: Hematopoietic stem cell transplantation
Sponsor:   Masonic Cancer Center, University of Minnesota
Recruiting
Body: Conditions:   Sickle Cell Disease;   Thalassemia;   Severe Congenital Neutropenia;   Diamond-Blackfan Anemia;   Shwachman-Diamond Syndrome
Interventions:   Drug: Busulfan, Fludarabine, ATG, TLI;   Drug: Busulfan, Cyclophosphamide, ATG, GCSF;   Drug: Campath, Fludarabine, Cyclophosphamide;   Radiation: Total Body Irradiation;   Procedure: Stem cell infusion
Sponsors:   Masonic Cancer Center, University of Minnesota;   National Marrow Donor Program
Active, not recruiting
Body: Conditions:   Leukemia, Myeloid, Chronic;   AML;   Leukemia, Lymphocytic, Acute;   MDS;   Leukemia, Lymphocytic, Chronic;   JMML;   Hodgkin's Disease;   Non-hodgkin's Lymphoma;   Multiple Myeloma
Interventions:   Procedure: Stem Cell Transplant;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Busulfan
Sponsor:   Masonic Cancer Center, University of Minnesota
Recruiting - verified July 2017
Body: Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Biological: anti-thymocyte globulin;   Biological: graft-versus-tumor induction therapy;   Biological: sargramostim;   Biological: therapeutic allogeneic lymphocytes;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: methylprednisolone;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: umbilical cord blood transplantation
Sponsor:   Roswell Park Cancer Institute
Active, not recruiting - verified March 2017
Body: Condition:   Severe Combined Immunodeficiency Syndrome
Intervention:   Drug: CD34+ cells transduced with ADA retrovir
Sponsor:   National Human Genome Research Institute (NHGRI)
Completed - verified September 17, 2014
Body: Conditions:   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions:   Biological: anti-thymocyte globulin;   Biological: filgrastim;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: methylprednisolone;   Procedure: bone marrow ablation with stem cell support;   Procedure: umbilical cord blood transplantation;   Radiation: radiation therapy
Sponsor:   Roswell Park Cancer Institute
Active, not recruiting - verified March 2017

Pages